Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2'-MOE-Modified Antisense Oligonucleotide

Toxicological Sciences : an Official Journal of the Society of Toxicology
Padmakumar NarayananScott P Henry

Abstract

ISIS 104838, a 2'-O-methoxyethyl (2'-MOE)-modified antisense oligonucleotide (ASO), causes a moderate, reproducible, dose-dependent, but selflimiting decrease in platelet (PLT) counts in monkeys and humans. To determine the etiology of PLT decrease in cynomolgus monkeys, a 12-week repeat dose toxicology study in 5 cynomolgus monkeys given subcutaneous injections of ISIS 104838 (30-60 mg/kg/week). Monkeys were also injected intravenously with 111Indium(In)-oxine-labeled PLTs to investigate PLT sequestration. In response to continued dosing, PLT counts were decreased by 50%-90% by day 30 in all monkeys. PLT decreases were accompanied by 2- to 4.5-fold increases in immunoglobulin M(IgM), which were typified by a 2- to 5-fold increase in antiplatelet factor 4 (antiPF4) IgM and antiPLT IgM, respectively. Monocyte chemotactic protein 1 increased upon dosing of ISIS 104838, concomitant with a 2- to 6-fold increase in monocyte-derived extracellular vesicles (EVs), indicating monocyte activation but not PLT activation. Despite a 2- to 3-fold increase in von Willebrand factor antigen in all monkeys following ASO administration, only 2 monkeys showed a 2- to 4-fold increase in endothelial EVs. Additionally, a ∼60 - 80%% increase in PLT se...Continue Reading

References

Apr 1, 1985·The Journal of Clinical Investigation·D B CinesA D Schreiber
Mar 23, 2001·Nature Immunology·A ShibuyaH Nakauchi
Jul 4, 2001·The Journal of Laboratory and Clinical Medicine·G P VisentinR H Aster
Jul 14, 2001·Molecular Immunology·M Boes
Aug 23, 2002·The New England Journal of Medicine·Joel L Moake
Nov 25, 2003·Clinical and Experimental Immunology·L Tasker, S Marshall-Clarke
Apr 2, 2005·British Journal of Haematology·Koichi KokameToshiyuki Miyata
Feb 22, 2008·Current Topics in Medicinal Chemistry·Saravanababu MurugesanRobert J Linhardt
Nov 11, 2008·Journal of Pharmaceutical and Biomedical Analysis·Gopi ShankarEugen Koren
Apr 7, 2009·Journal of Thrombosis and Haemostasis : JTH·R H AsterD W Bougie
Apr 14, 2009·The Journal of Clinical Investigation·Meng-Yun ChouChristoph J Binder
Sep 28, 2010·Cellular & Molecular Immunology·Aiko-Konno ShirakawaJoshua M Farber
May 4, 2012·Toxicologic Pathology·Michael J SantostefanoNancy Everds
Jul 5, 2012·Current Opinion in Hematology·John W Semple, Drew Provan
Dec 13, 2012·Expert Opinion on Drug Metabolism & Toxicology·Rosie Z YuRichard S Geary
Apr 2, 2013·Current Opinion in Pharmacology·Gregor LeibundgutSotirios Tsimikas
Oct 11, 2014·The Journal of Pharmacology and Experimental Therapeutics·Lijiang ShenScott P Henry
Feb 4, 2015·The Journal of Experimental Medicine·Ulrike FlierlKarlheinz Peter
Mar 3, 2015·Thrombosis Research·Michele M TanaTheo Heller
Jun 23, 2015·Journal of Thrombosis and Haemostasis : JTH·A Greinacher, M Delcea
Oct 21, 2015·BMC Cardiovascular Disorders·Jonathan W YauSubodh Verma
Oct 21, 2015·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Samuel A StonerJohn P Nolan
Jun 28, 2016·Nature Reviews. Immunology·Christoph J BinderJoseph L Witztum
Jan 13, 2017·PloS One·Marjory B BrooksAlbert E Schultze
Feb 15, 2017·Proceedings of the National Academy of Sciences of the United States of America·David FrescasAndrei V Gudkov

❮ Previous
Next ❯

Citations

Oct 5, 2018·Annual Review of Pharmacology and Toxicology·C I Edvard Smith, Rula Zain
May 22, 2019·Current Atherosclerosis Reports·Marja-Riitta TaskinenJan Borén
May 18, 2019·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Rula Zain, C I Edvard Smith
Feb 5, 2021·Thrombosis Research·Alexander ZaslavskyGanesh S Palapattu
Mar 6, 2021·Journal of the American College of Cardiology·R Scott WrightUNKNOWN ORION Phase III Investigators
Mar 12, 2021·Current Atherosclerosis Reports·Ioannis AkoumianakisTheodosios D Filippatos
Apr 7, 2021·EMBO Molecular Medicine·Suzan M HammondVirginia Arechavala-Gomeza

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Nihon rinsho. Japanese journal of clinical medicine
Y Takahashi
Nihon rinsho. Japanese journal of clinical medicine
Takeshi Shimomura, Akirou Kimura
Annals of the New York Academy of Sciences
H J Weiss
© 2022 Meta ULC. All rights reserved